Uterine (Endometrial) Cancer - Symptoms, Causes, Treatment & Prevention

📅 Updated: June 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Uterine (Endometrial) Cancer – Comprehensive Medical Guide

Uterine (Endometrial) Cancer – A Complete Patient‑Friendly Guide

Overview

Uterine cancer, most commonly called **endometrial cancer**, is a malignancy that begins in the lining of the uterus (the endometrium). It is the **most common gynecologic cancer in high‑income countries**, accounting for roughly **6% of all cancers in women** worldwide.

Who it affects

  • Women ages **50–70** are at highest risk, with a median diagnosis age of 63 years.
  • Although rare, it can occur in younger women, especially those with hereditary cancer syndromes (e.g., Lynch syndrome).
  • It is far more common in **post‑menopausal** women because of prolonged exposure to estrogen without progesterone opposition.

Prevalence

  • In the United States, an estimated **66,000 new cases** are diagnosed each year (2024 data, CDC).
  • Lifetime risk for a woman in the U.S. is about **1 in 37**.
  • Survival varies by stage: 5‑year survival is **≈ 95%** for cancer confined to the uterus (stage I) but drops to **≈ 17%** for distant metastatic disease (stage IV) (Mayo Clinic).

Symptoms

Early‑stage endometrial cancer often presents with subtle changes that can be mistaken for normal menopause symptoms. Any new or persistent change should be evaluated by a health professional.

Typical symptoms

  • Abnormal uterine bleeding – any bleeding after menopause, irregular periods, or heavy menstrual flow.
  • Spotting or discharge between periods.
  • Pelvic pain or pressure – often a dull ache that may worsen after intercourse.
  • Unexplained weight loss – especially when paired with other symptoms.
  • Swelling in the legs or abdomen – may indicate spread to lymph nodes or ascites.

Less common signs

  • Blood in the urine (if cancer invades the bladder).
  • Persistent constipation or changes in bowel habits.
  • Fatigue or anemia from chronic bleeding.

Most women notice abnormal bleeding first; that symptom alone accounts for **> 90%** of early diagnoses (Cleveland Clinic).

Causes and Risk Factors

Endometrial cancer is typically driven by hormonal, genetic, and lifestyle influences.

Hormonal factors

  • Estrogen dominance – prolonged exposure to estrogen without progesterone (e.g., obesity, polycystic ovary syndrome, early menarche, late menopause).
  • Unopposed estrogen therapy – estrogen‑only hormone replacement therapy (HRT) increases risk 2–5 fold.
  • Tamoxifen – a breast‑cancer drug that acts as an estrogen agonist in the uterus.

Genetic predisposition

  • Lynch syndrome (hereditary non‑polyposis colorectal cancer) – 2‑5% of endometrial cancers; mutation in DNA mismatch‑repair genes (MLH1, MSH2, MSH6, PMS2).
  • BRCA1/2 – modestly increased risk, especially when combined with other factors.

Other risk factors

  • Obesity (BMI ≥ 30) – each 5‑unit increase in BMI raises risk by ~20% (NIH).
  • Diabetes or insulin resistance.
  • Nulliparity or never having been pregnant.
  • Family history of endometrial or colorectal cancer.
  • Radiation exposure to the pelvic area.
  • Age > 50 years.

Diagnosis

When a clinician suspects endometrial cancer, a stepwise approach is used to confirm the diagnosis, determine the stage, and guide treatment.

Initial evaluation

  • Medical history & physical exam – focus on bleeding patterns, risk factors, and pelvic exam.
  • Transvaginal ultrasound (TVUS) – assesses endometrial thickness; a thickness > 4–5 mm in post‑menopausal women often prompts further testing.

Definitive tissue diagnosis

  • Endometrial biopsy (office pipelle) – simple, office‑based sampling.
  • Dilation & curettage (D&C) – more extensive sampling, typically done under anesthesia.
  • Hysteroscopy‑directed biopsy – visual inspection of the uterine cavity with targeted sampling.

Staging work‑up (after a cancer diagnosis)

  • Pelvic MRI – evaluates depth of myometrial invasion and cervical involvement.
  • CT scan of chest/abdomen/pelvis – looks for lymph node involvement or distant metastasis.
  • PET‑CT – useful for detecting metabolically active metastatic disease.
  • Laparoscopic surgical staging – may be combined with definitive surgery to assess lymph nodes.

Staging follows the FIGO (International Federation of Gynecology and Obstetrics) system, ranging from stage I (confined to uterus) to stage IV (spread to distant organs).

Treatment Options

Treatment is individualized based on stage, tumor grade, molecular profile, patient health, and fertility desires.

Surgery – the cornerstone

  • Total hysterectomy (removal of uterus and cervix) + bilateral salpingo‑oophorectomy** (removal of both ovaries and fallopian tubes).**
  • Lymph node assessment – sentinel‑node mapping or systematic pelvic/para‑aortic node dissection.
  • For young women wishing to preserve fertility, high‑dose progestin therapy or conservative hysterectomy may be considered in very early, low‑grade disease.

Radiation therapy

  • External beam radiation therapy (EBRT) – directed at pelvis, reduces local recurrence.
  • Vaginal brachytherapy – high‑dose radiation placed inside the vagina; often used after surgery for high‑risk early stages.

Systemic (medical) therapy

  • Hormonal therapy – high‑dose progestins (medroxyprogesterone acetate, megestrol acetate) for low‑grade or fertility‑preserving cases.
  • Chemotherapy – carboplatin + paclitaxel is standard for advanced or high‑grade disease.
  • Targeted therapy – pembrolizumab (PD‑1 inhibitor) for tumors with microsatellite instability‑high (MSI‑H) or mismatch‑repair deficiency (dMMR); trastuzumab for HER2‑positive serous carcinoma.
  • Immunotherapy – pembrolizumab alone or with lenvatinib for selected recurrent/metastatic cases.

Lifestyle & supportive measures

  • Weight management, smoking cessation, and regular exercise improve outcomes and reduce recurrence risk.
  • Psychosocial support, pelvic floor therapy, and sexual health counseling are essential parts of comprehensive care.

Living with Uterine (Endometrial) Cancer

After treatment, many women face physical and emotional adjustments. Below are practical strategies to support daily life.

Follow‑up care

  • First 2 years: visits every 3–4 months (history, pelvic exam, imaging if indicated).
  • Years 3–5: visits every 6 months.
  • After 5 years: annual visits for most patients.
  • Report any new bleeding, pelvic pain, or unexplained weight loss promptly.

Managing side effects

  • Lymphedema – wear compression sleeves, perform gentle lymphatic drainage exercises.
  • Vaginal shortening/stenosis – use vaginal dilators or moisturizers; discuss estrogen‑free lubricants with your provider.
  • Fatigue – prioritize sleep, moderate aerobic activity, and balanced nutrition.
  • Emotional health – consider counseling, support groups (e.g., Gilda’s Club), or mindfulness programs.

Nutrition & activity

  • Aim for a Mediterranean‑style diet rich in fruits, vegetables, whole grains, fish, and healthy fats.
  • Maintain a BMI < 25 kg/m² when possible; modest weight loss (5–10%) can improve hormone balance.
  • At least 150 minutes of moderate‑intensity aerobic activity weekly, plus strength training twice per week.

Fertility & sexual health

  • If fertility was preserved, discuss timed intercourse or assisted reproductive technologies with a reproductive endocrinologist.
  • Address changes in libido or pain during intercourse with a pelvic floor therapist or sexual health specialist.

Prevention

While no method guarantees protection, several evidence‑based actions lower the risk of developing endometrial cancer.

  • Weight control – maintain a healthy BMI; a 5% weight loss can reduce estrogen‑related risk.
  • Physical activity – regular exercise improves insulin sensitivity and hormone regulation.
  • Balanced hormonal therapy – if HRT is needed, use the lowest effective dose of combined estrogen‑plus‑progestin rather than estrogen‑only.
  • Manage diabetes – keep blood glucose under control through diet, medication, and lifestyle.
  • Screen high‑risk families – women with Lynch syndrome should begin annual endometrial sampling or transvaginal ultrasound at age 30–35 (CDC).
  • Contraceptive use – combined oral contraceptives reduce risk by up to 50% with long‑term use; discuss benefits and risks with your clinician.

Complications

If left untreated or if cancer recurs, several complications may arise:

  • Local invasion – spread to the cervix, bladder, or rectum causing urinary urgency, hematuria, or bowel obstruction.
  • Metastasis – common sites include lungs, liver, and bone; can lead to respiratory distress or pathological fractures.
  • Severe anemia – from chronic uterine bleeding, leading to fatigue, dyspnea, or cardiac strain.
  • Venous thromboembolism (VTE) – cancer and obesity increase clot risk.
  • Psychological impact – anxiety, depression, and body‑image concerns are frequent and may require professional support.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

  • Sudden, heavy vaginal bleeding that soaks a pad in less than an hour.
  • Severe pelvic or abdominal pain accompanied by fever (> 38°C / 100.4°F).
  • Signs of a blood clot – sudden leg swelling, pain, or shortness of breath.
  • Unexplained fainting, dizziness, or rapid heart rate.
  • Profuse vomiting or inability to keep fluids down (may signal bowel obstruction).

These symptoms could indicate a medical emergency such as hemorrhage, infection, or a clot.

References

```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References